<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002480</url>
  </required_header>
  <id_info>
    <org_study_id>91-022</org_study_id>
    <secondary_id>CDR0000077099</secondary_id>
    <secondary_id>NCI-V91-0102</secondary_id>
    <nct_id>NCT00002480</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Phase I Study of 3-Dimensional Conformal Radiotherapy in Patients With Locally Advanced (Stage T2c and T3) Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation therapy
      may be an effective treatment for prostate cancer.

      PURPOSE: Phase I trial to study the effectiveness of radiation therapy in treating patients
      who have stage II or stage III prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of radiotherapy using 3-dimensional (3D)
      conformal techniques in patients with stage II or III adenocarcinoma of the prostate. II.
      Determine the morbidity of high-dose 3D conformal therapy in these patients.

      OUTLINE: This is a dose escalation study. Patients undergo 3-dimensional conformal
      radiotherapy 4-5 days a week for at least 8 weeks. Cohorts of 20-40 patients receive
      escalating doses of radiotherapy until the maximum tolerated dose (MTD) is determined. The
      MTD is defined as the dose at which no more than 10% of patients experience dose-limiting
      toxicity. Patients are followed at 3 months, every 6 months for 5 years, and then annually
      thereafter.

      PROJECTED ACCRUAL: A minimum of 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1991</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Locally advanced (T2c-T3) adenocarcinoma of the prostate
        including: Bulky tumors confined to prostate (stage II) Tumors extending beyond capsule
        (stage III) PSA no greater than 20 ng/mL No regional lymph node involvement (by CT scan or
        surgical sampling) No distant metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: WBC greater than 4,000/mm3 Platelet count greater
        than 100,000/mm3 Hemoglobin greater than 11 g/dL Hepatic: Not specified Renal: Not
        specified Other: No major medical or psychiatric illness that would preclude study No
        metallic pelvic prosthesis

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No
        prior chemotherapy Endocrine therapy: Prior hormonal therapy allowed Radiotherapy: No prior
        radiotherapy (including pelvic irradiation) Surgery: No prior radical surgery for carcinoma
        of the prostate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Zelefsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Leibel SA, Heimann R, Kutcher GJ, Zelefsky MJ, Burman CM, Melian E, Orazem JP, Mohan R, LoSasso TJ, Lo YC, et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):55-65.</citation>
    <PMID>7505776</PMID>
  </results_reference>
  <results_reference>
    <citation>Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, Fuks Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol. 1994 Nov;152(5 Pt 2):1792-8.</citation>
    <PMID>7933238</PMID>
  </results_reference>
  <results_reference>
    <citation>Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R, Mageras GS, Ling CC, Fuks Z. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol. 1994 Oct;21(5):580-97. Review.</citation>
    <PMID>7939749</PMID>
  </results_reference>
  <results_reference>
    <citation>Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):755-61.</citation>
    <PMID>8040021</PMID>
  </results_reference>
  <results_reference>
    <citation>Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am. 1995 Jul-Aug;1(2):142-50.</citation>
    <PMID>9166467</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2004</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

